AXA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.93 EUR | +1.28% |
|
+3.03% | +4.88% |
| 24/06 | Publicis : Publicis Conseil wins Cannes Lions award | CF |
| 21/06 | German Association of Cities: More houses need natural hazard insurance | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its low valuation, with P/E ratio at 8.75 and 8.04 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Ratings chart - Surperformance
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.88% | 72.97B | - | ||
| +9.61% | 51.38B | B | ||
| +9.06% | 51.29B | B+ | ||
| +22.23% | 46.92B | B+ | ||
| +14.90% | 42.79B | B+ | ||
| +23.84% | 39.24B | B | ||
| +19.81% | 34.15B | B | ||
| -2.40% | 28.48B | B | ||
| +31.80% | 27.32B | A | ||
| -10.88% | 26.7B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CS Stock
- AXA Stock
- Ratings AXA
